Compare · PETS vs YI
PETS vs YI
Side-by-side comparison of PetMed Express Inc. (PETS) and 111 Inc. (YI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PETS and YI operate in Retail-Drug Stores and Proprietary Stores (Consumer Staples), so they compete in similar markets.
- PETS is the larger of the two at $41.9M, about 1.3x YI ($33.2M).
- Over the past year, PETS is down 41.9% and YI is down 48.1% - PETS leads by 6.2 points.
- PETS has hit the wire 3 times in the past 4 weeks while YI has been quiet.
- PETS has more recent analyst coverage (6 ratings vs 0 for YI).
- Company
- PetMed Express Inc.
- 111 Inc.
- Price
- $1.98+1.02%
- $3.90+1.30%
- Market cap
- $41.9M
- $33.2M
- 1M return
- +11.86%
- -13.24%
- 1Y return
- -41.94%
- -48.14%
- Industry
- Retail-Drug Stores and Proprietary Stores
- Retail-Drug Stores and Proprietary Stores
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 3
- 0
- Recent ratings
- 6
- 0
PetMed Express Inc.
PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes. The company also sells food, beds, crates, stairs, strollers, and other pet supplies. It sells its products through its Internet website and mobile app; telephone contact center; and direct mail/print through catalogs, brochures, and postcards. PetMed Express, Inc. was incorporated in 1996 and is headquartered in Delray Beach, Florida.
111 Inc.
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2B and B2C. The company sells medical and wellness products through online retail, and wholesale and retail pharmacies, as well as provides value-added services, such as online consultation services and e-prescription services to consumers. Its product portfolio comprises prescription and over-the counter drugs, such as western and traditional Chinese medicinal drugs; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices, including bandages and thermometers; and personal care products, such as skin care, birth control, and sexual wellness products; and baby products. The company also operates an online marketplace where third-party sellers can directly sell to pharmacies; provides online loan application services to the clients of 1 Drug Mall, including pharmacies and wholesalers; and digital contract sales organization and data services. As of December 31, 2020, it operated 13 offline retail pharmacies under the Yi Hao Pharmacy brand name in Guangzhou, Wuhan, Tianjin, and Kunshan. In addition, the company offers warehousing, logistics, procurement, research and development, and consulting services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies and distributors, medical professionals, and insurance companies. 111, Inc. has strategic partnerships with Bayer Healthcare Co. Ltd.; BeiGene, Ltd.; and Jianming Pharmaceutical Group. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Latest PETS
- PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform
- PetMed Express, Inc. Confirms Receipt of Unsolicited, Non-Binding, and Conditional Acquisition Proposal from SilverCape Investments Limited
- SilverCape Releases Revised Proposal to Acquire PetMed Express for $3.00 per Share in Cash
- PetMed Express Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CAO and Interim CFO Krulik Douglas was granted 32,500 shares, increasing direct ownership by 46% to 102,500 units (SEC Form 4)
- SEC Form DEFA14A filed by PetMed Express Inc.
- SEC Form DEF 14A filed by PetMed Express Inc.
- Large owner Nina Capital Holdings Inc. bought $43,725 worth of shares (25,000 units at $1.75), increasing direct ownership by 0.97% to 2,600,000 units (SEC Form 4)
- SEC Form 10-K filed by PetMed Express Inc.
- PetMed Express Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest YI
- Director Chen Yang Luke was granted 594,222 units of RSUs and sold $22,840 worth of RSUs (98,760 units at $0.23) (SEC Form 4) to cover withholding tax
- Director Sun Jian David was granted 810,271 units of RSUs and sold $92,749 worth of RSUs (397,060 units at $0.23) (SEC Form 4) (withholding tax)
- Director Sun Jian David was granted 810,271 units of RSUs and sold $79,225 worth of RSUs (338,260 units at $0.23) (SEC Form 4) (tax liability)
- Director Sun Jian David was granted 810,271 units of RSUs and sold $53,672 worth of RSUs (227,160 units at $0.24) (SEC Form 4) to satisfy tax liability
- SEC Form 6-K filed by 111 Inc.
- 111, Inc. Announces First Quarter 2026 Unaudited Financial Results
- Director Luo Jun Justin was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to cover taxes
- Director Sun Jian David was granted 810,271 units of RSUs and sold $25,516 worth of RSUs (99,720 units at $0.26) (SEC Form 4) to satisfy withholding obligation
- Director Chen Yang Luke was granted 594,222 units of RSUs and sold $1,239 worth of RSUs (4,840 units at $0.26) (SEC Form 4) to satisfy withholding tax
- Director Teo Nee Chuan gave a grant of 811,889 units of RSUs, increasing direct ownership by 1,931% to 811,889 units (SEC Form 4)